LPCN highlights encouraging interim safety for LPCN 1154 in Phase 3 PPD
Rhea-AI Filing Summary
Lipocine Inc. (LPCN) reported that it has issued a press release highlighting a promising interim safety profile for its investigational drug LPCN 1154 in a Phase 3 clinical trial for postpartum depression (PPD). The company describes these findings as interim safety results, meaning the study is still ongoing but, so far, the treatment has shown a favorable safety profile in participants.
The press release containing more detail is furnished as Exhibit 99.1 to this report and is incorporated by reference, while no specific efficacy data or numerical safety outcomes are provided in this summary. The update signals continued clinical progress of LPCN 1154 in a late-stage trial targeting postpartum depression, a serious mood disorder affecting women after childbirth.
Positive
- None.
Negative
- None.
Insights
Lipocine reports encouraging interim safety for LPCN 1154 in Phase 3 PPD.
Lipocine highlights a promising interim safety profile for LPCN 1154 in an ongoing Phase 3 postpartum depression trial. Interim safety readouts are important checkpoints in late-stage development because they indicate whether a drug remains suitable for continued testing in a larger patient population.
The disclosure focuses on safety and does not provide efficacy data or detailed event rates, so it mainly informs on trial continuity rather than outcomes. Still, a positive safety update at this stage reduces one key area of uncertainty that can halt or alter trials.
The detailed information is contained in the press release furnished as Exhibit 99.1, and future clinical updates will be needed to understand efficacy, durability of effect, and the overall benefit-risk profile of LPCN 1154 in postpartum depression.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
On November 18, 2025, the Company issued a press release highlighting the promising interim safety profile of LPCN 1154 in our Phase 3 clinical trial in postpartum depression (PPD). A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibits are filed with this report:
| Exhibit No. | Description | |
| 99.1 | Press Release Highlighting Promising Interim Safety Profile in Phase 3 Clinical Trial of LPCN 1154 in Postpartum Depression (PPD) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIPOCINE INC. | ||||
| Date: | November 18, 2025 | By: | /s/ Mahesh V. Patel | |
| Mahesh V. Patel | ||||
| President and Chief Executive Officer | ||||
FAQ
What did Lipocine Inc. (LPCN) announce in this 8-K filing?
Lipocine Inc. announced that it issued a press release highlighting a promising interim safety profile for its drug candidate LPCN 1154 in a Phase 3 trial for postpartum depression.
What is LPCN 1154 and what condition is it being tested for?
LPCN 1154 is an investigational drug being evaluated in a Phase 3 clinical trial for the treatment of postpartum depression (PPD).
What stage is Lipocine’s postpartum depression trial in?
The trial of LPCN 1154 for postpartum depression is in Phase 3, which is a late-stage clinical trial designed to evaluate safety and effectiveness in a larger patient group.
What new information about safety did Lipocine provide?
Lipocine stated that interim data from its Phase 3 trial show a promising safety profile for LPCN 1154 in patients with postpartum depression, based on results collected so far.
Where can investors find more details about the LPCN 1154 interim safety data?
More detail is provided in the press release furnished as Exhibit 99.1 to the report, which is incorporated by reference.
Does this 8-K filing include efficacy results for LPCN 1154?
No, the filing only mentions a promising interim safety profile for LPCN 1154 in the Phase 3 trial for postpartum depression; it does not provide specific efficacy results.
